The Lancet. Infectious diseases · 2026
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rouphael Nadine, Baqar Shahida, Dickey Michelle, Quigley Christina, Pham Tena, Adams Josh, Kwatra Gaurav, Bechnak Sarah, Smith Veronica, Scherer Erin M, Graciaa Daniel S, El-Khorazaty Jill, Fraser Jamie A, Heard Susan, Cato Krista, Mejia-Galvis Jorge, Barnoy Shoshana, Chandrasekharan Lakshmi, Porter Chad K, Suvarnapunya Akamol E, Venkatesan Malabi M, Frenck Robert W, DMID 17-0112 Study Group
Аннотация
BACKGROUND: Despite long-standing research, no licensed vaccine exists for shigella, a leading cause of bacterial diarrhoea and dysentery. WRSs2 is a live-attenuated Shigella sonnei vaccine candidate which has previously shown safety and immunogenicity. In this trial, we evaluated its safety and efficacy in a controlled human infection model.
METHODS: In this phase 2, double-blind, randomised, placebo-controlled trial at two sites in the USA, healthy adults aged 18-49 years were assigned using a site-stratified permuted-block schedule. The original three-arm design allocated participants 1:1:1 to two-dose WRSs2 (106 colony-forming units [CFU]), one-dose placebo followed by one-dose WRSs2 (106 CFU), or two-dose placebo; doses were given 28 days apart. After 69 participants were enrolled, a Data and Safety Monitoring Board (DSMB)-triggered safety review and protocol amendment resulted in subsequent participants being assigned 2:1 to two-dose WRSs2 (5 × 105 CFU) or placebo. Participants were challenged orally 28 days after the second vaccination with approximately 1·5 × 103 CFU of S sonnei 53G. The primary endpoint was endpoint review committee-adjudicated shigellosis in challenged participants. Safety was assessed in all vaccinated participants. This trial is registered with ClinicalTrials.gov, NCT04242264. The trial is complete.
FINDINGS: Between Oct 11, 2022, and Jan 9, 2024, 108 participants were enrolled, with 22 assigned to two-dose 106CFU, 26 to two-dose 5 × 105 CFU, 23 to one-dose 106 CFU, and 37 to placebo. 73 participants underwent challenge (16, 18, 13, and 26 participants in the respective groups). Endpoint review committee-adjudicated shigellosis occurred in three (9%) of 34 participants given pooled two-dose vaccine and 21 (81%) of 26 placebo recipients (vaccine efficacy 89% [95% CI 71-96]; p<0·0001). Six participants had grade 3 post-vaccination adverse events, prompting two DSMB reviews; after the first review, the protocol was amended to reduce the vaccine dose and revise eligibility criteria. There was no change after the second review. No vaccine-related serious adverse events or deaths occurred.
INTERPRETATION: In adults in the USA, WRSs2 provided high-level protection against S sonnei shigellosis. Although protection was substantial, the occurrence of a few self-limiting grade 3 adverse events indicates that further optimisation is needed to better define the safety-efficacy balance. These findings support further clinical development of live-attenuated shigella vaccines.
FUNDING: US National Institutes of Health with pharmaceutical support from the US Department of Defense.
METHODS: In this phase 2, double-blind, randomised, placebo-controlled trial at two sites in the USA, healthy adults aged 18-49 years were assigned using a site-stratified permuted-block schedule. The original three-arm design allocated participants 1:1:1 to two-dose WRSs2 (106 colony-forming units [CFU]), one-dose placebo followed by one-dose WRSs2 (106 CFU), or two-dose placebo; doses were given 28 days apart. After 69 participants were enrolled, a Data and Safety Monitoring Board (DSMB)-triggered safety review and protocol amendment resulted in subsequent participants being assigned 2:1 to two-dose WRSs2 (5 × 105 CFU) or placebo. Participants were challenged orally 28 days after the second vaccination with approximately 1·5 × 103 CFU of S sonnei 53G. The primary endpoint was endpoint review committee-adjudicated shigellosis in challenged participants. Safety was assessed in all vaccinated participants. This trial is registered with ClinicalTrials.gov, NCT04242264. The trial is complete.
FINDINGS: Between Oct 11, 2022, and Jan 9, 2024, 108 participants were enrolled, with 22 assigned to two-dose 106CFU, 26 to two-dose 5 × 105 CFU, 23 to one-dose 106 CFU, and 37 to placebo. 73 participants underwent challenge (16, 18, 13, and 26 participants in the respective groups). Endpoint review committee-adjudicated shigellosis occurred in three (9%) of 34 participants given pooled two-dose vaccine and 21 (81%) of 26 placebo recipients (vaccine efficacy 89% [95% CI 71-96]; p<0·0001). Six participants had grade 3 post-vaccination adverse events, prompting two DSMB reviews; after the first review, the protocol was amended to reduce the vaccine dose and revise eligibility criteria. There was no change after the second review. No vaccine-related serious adverse events or deaths occurred.
INTERPRETATION: In adults in the USA, WRSs2 provided high-level protection against S sonnei shigellosis. Although protection was substantial, the occurrence of a few self-limiting grade 3 adverse events indicates that further optimisation is needed to better define the safety-efficacy balance. These findings support further clinical development of live-attenuated shigella vaccines.
FUNDING: US National Institutes of Health with pharmaceutical support from the US Department of Defense.